136 related articles for article (PubMed ID: 34871862)
1. miR-197-5p increases Doxorubicin-mediated anticancer cytotoxicity of HT1080 fibrosarcoma cells by decreasing drug efflux.
Jain N; Das B; Mallick B
DNA Repair (Amst); 2022 Jan; 109():103259. PubMed ID: 34871862
[TBL] [Abstract][Full Text] [Related]
2. miR-199a-5p is involved in doxorubicin resistance of non-small cell lung cancer (NSCLC) cells.
Jin Y; Wang H; Zhu Y; Feng H; Wang G; Wang S
Eur J Pharmacol; 2020 Jul; 878():173105. PubMed ID: 32278855
[TBL] [Abstract][Full Text] [Related]
3. miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A.
Zhang Y; He Y; Lu LL; Zhou ZY; Wan NB; Li GP; He X; Deng HW
Kaohsiung J Med Sci; 2019 Jan; 35(1):17-23. PubMed ID: 30844143
[TBL] [Abstract][Full Text] [Related]
4. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
[TBL] [Abstract][Full Text] [Related]
5. P53-miR-191-
Sharma S; Nagpal N; Ghosh PC; Kulshreshtha R
RNA; 2017 Aug; 23(8):1237-1246. PubMed ID: 28450532
[TBL] [Abstract][Full Text] [Related]
6. piR-39980 mediates doxorubicin resistance in fibrosarcoma by regulating drug accumulation and DNA repair.
Das B; Jain N; Mallick B
Commun Biol; 2021 Nov; 4(1):1312. PubMed ID: 34799689
[TBL] [Abstract][Full Text] [Related]
7. miR-197-5p inhibits sarcomagenesis and induces cellular senescence via repression of KIAA0101.
Jain N; Roy J; Das B; Mallick B
Mol Carcinog; 2019 Aug; 58(8):1376-1388. PubMed ID: 31001891
[TBL] [Abstract][Full Text] [Related]
8. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia.
Feng DD; Zhang H; Zhang P; Zheng YS; Zhang XJ; Han BW; Luo XQ; Xu L; Zhou H; Qu LH; Chen YQ
J Cell Mol Med; 2011 Oct; 15(10):2164-75. PubMed ID: 21070600
[TBL] [Abstract][Full Text] [Related]
9. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.
Lai J; Yang H; Zhu Y; Ruan M; Huang Y; Zhang Q
BMC Cancer; 2019 Jun; 19(1):602. PubMed ID: 31215481
[TBL] [Abstract][Full Text] [Related]
10. Circ_0003998 enhances doxorubicin resistance in hepatocellular carcinoma by regulating miR-218-5p/EIF5A2 pathway.
Li X; He J; Ren X; Zhao H; Zhao H
Diagn Pathol; 2020 Dec; 15(1):141. PubMed ID: 33308276
[TBL] [Abstract][Full Text] [Related]
11. miR-520b Inhibits IGF-1R to Increase Doxorubicin Sensitivity and Promote Cell Apoptosis in Breast Cancer.
Zhang H; Zheng XD; Zeng XH; Li L; Zhou Q
Yakugaku Zasshi; 2021 Mar; 141(3):415-426. PubMed ID: 33116033
[TBL] [Abstract][Full Text] [Related]
12. MiR-15b-5p is Involved in Doxorubicin-Induced Cardiotoxicity via Inhibiting Bmpr1a Signal in H9c2 Cardiomyocyte.
Wan GX; Cheng L; Qin HL; Zhang YZ; Wang LY; Zhang YG
Cardiovasc Toxicol; 2019 Jun; 19(3):264-275. PubMed ID: 30535663
[TBL] [Abstract][Full Text] [Related]
13. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis.
Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S
Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937
[TBL] [Abstract][Full Text] [Related]
14. Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways.
Lehnhardt M; Klein-Hitpass L; Kuhnen C; Homann HH; Daigeler A; Steinau HU; Roehrs S; Schnoor L; Steinstraesser L; Mueller O
BMC Cancer; 2005 Jul; 5():74. PubMed ID: 16001973
[TBL] [Abstract][Full Text] [Related]
15. LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22.
Zhu K; Yuan Y; Wen J; Chen D; Zhu W; Ouyang Z; Wang W
Aging (Albany NY); 2020 Apr; 12(8):6644-6666. PubMed ID: 32302291
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Therapy of Doxorubicin and miR-129-5p with Self-Cross-Linked Bioreducible Polypeptide Nanoparticles Reverses Multidrug Resistance in Cancer Cells.
Yi H; Liu L; Sheng N; Li P; Pan H; Cai L; Ma Y
Biomacromolecules; 2016 May; 17(5):1737-47. PubMed ID: 27029378
[TBL] [Abstract][Full Text] [Related]
17. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.
Xu F; Liao JZ; Xiang GY; Zhao PX; Ye F; Zhao Q; He XX
Cancer Med; 2017 Mar; 6(3):651-661. PubMed ID: 28135055
[TBL] [Abstract][Full Text] [Related]
18. MiR-122 Reverses the Doxorubicin-Resistance in Hepatocellular Carcinoma Cells through Regulating the Tumor Metabolism.
Pan C; Wang X; Shi K; Zheng Y; Li J; Chen Y; Jin L; Pan Z
PLoS One; 2016; 11(5):e0152090. PubMed ID: 27138141
[TBL] [Abstract][Full Text] [Related]
19. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line.
Shaik MS; Chatterjee A; Singh M
J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869
[TBL] [Abstract][Full Text] [Related]
20. P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.
Long X; Lin XJ
J Cell Biochem; 2019 Apr; 120(4):5652-5665. PubMed ID: 30387173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
